A trial court properly dismissed a securities suit by Karyopharm Therapeutics Inc. investors saying it misled them about the safety and efficacy of its cancer drug selinexor, the First Circuit ruled.
Lead plaintiff Myo Thant failed to adequately allege Karyopharm made misstatements about a selinexor clinical trial in a conference call, or material omissions in a press release, the appeals court said Aug. 5.
Selinexor, now sold under the name Xpovio, is marketed as part of a last-chance treatment for patients with multiple myeloma and acute myeloid leukemia that have persisted through other treatments or returned, according to the court. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.